<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35573643</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2475-0379</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Research and practice in thrombosis and haemostasis</Title>
          <ISOAbbreviation>Res Pract Thromb Haemost</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clustering extent-dependent differential signaling by CLEC-2 receptors in platelets.</ArticleTitle>
        <Pagination>
          <StartPage>e12710</StartPage>
          <MedlinePgn>e12710</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e12710</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/rth2.12710</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">C-type lectin receptor family members play a role in many cells including platelets, where they are crucial in the separation of lymphatic and blood vessels during development. The C-type lectin-like receptor 2 (CLEC-2) receptor contains the canonical intracellular hemITAM motif through which it signals to activate Syk.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">One proposed hypothesis for signaling cascade is that Syk bridges two receptors through phosphorylated hemITAM motifs. We demonstrated that the phosphorylated hemITAM stimulates PI3 kinase/Btk pathways to activate Syk. To address this controversy, we used a CLEC-2 selective agonist and studied the role of Btk in platelet activation.</AbstractText>
          <AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="UNASSIGNED">Platelet activation and downstream signaling were abolished in murine and human platelets in the presence of the Btk inhibitors ibrutinib or acalabrutinib when a low concentration of a CLEC-2 antibody was used to crosslink CLEC-2 receptors. This inhibition was overcome by increasing concentrations of the CLEC-2 antibody. Similar results were obtained in X-linked immunodeficient mouse platelets, with an inactivating mutation in Btk or in Lyn null platelets. We conclude that at low crosslinking conditions of CLEC-2, Btk plays an important role in the activation of Syk, but at higher crosslinking conditions their role becomes less important and other mechanisms take over to activate Syk.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dangelmaier</LastName>
            <ForeName>Carol</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-8941-7002</Identifier>
            <AffiliationInfo>
              <Affiliation>Sol Sherry Thrombosis Research Center Lewis Katz School of Medicine Temple University Philadelphia Pennsylvania USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vari</LastName>
            <ForeName>Hymavathi Reddy</ForeName>
            <Initials>HR</Initials>
            <AffiliationInfo>
              <Affiliation>Sol Sherry Thrombosis Research Center Lewis Katz School of Medicine Temple University Philadelphia Pennsylvania USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wright</LastName>
            <ForeName>Monica</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Sol Sherry Thrombosis Research Center Lewis Katz School of Medicine Temple University Philadelphia Pennsylvania USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kostyak</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <Identifier Source="ORCID">0000-0002-8712-1192</Identifier>
            <AffiliationInfo>
              <Affiliation>Sol Sherry Thrombosis Research Center Lewis Katz School of Medicine Temple University Philadelphia Pennsylvania USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kunapuli</LastName>
            <ForeName>Satya P</ForeName>
            <Initials>SP</Initials>
            <Identifier Source="ORCID">0000-0002-1298-3214</Identifier>
            <AffiliationInfo>
              <Affiliation>Sol Sherry Thrombosis Research Center Lewis Katz School of Medicine Temple University Philadelphia Pennsylvania USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Res Pract Thromb Haemost</MedlineTA>
        <NlmUniqueID>101703775</NlmUniqueID>
        <ISSNLinking>2475-0379</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">aggregation</Keyword>
        <Keyword MajorTopicYN="N">hemostasis</Keyword>
        <Keyword MajorTopicYN="N">platelet</Keyword>
        <Keyword MajorTopicYN="N">signal transduction</Keyword>
        <Keyword MajorTopicYN="N">thrombosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>4</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35573643</ArticleId>
        <ArticleId IdType="pmc">PMC9074038</ArticleId>
        <ArticleId IdType="doi">10.1002/rth2.12710</ArticleId>
        <ArticleId IdType="pii">RTH212710</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Zelensky AN, Gready JE. The C‐type lectin‐like domain superfamily. FEBS J. 2005;272:6179‐6217. doi:10.1111/j.1742-4658.2005.05031.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-4658.2005.05031.x</ArticleId>
            <ArticleId IdType="pubmed">16336259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Drickamer K, Taylor ME. Recent insights into structures and functions of C‐type lectins in the immune system. Curr Opin Struct Biol. 2015;34:26‐34. doi:10.1016/j.sbi.2015.06.003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sbi.2015.06.003</ArticleId>
            <ArticleId IdType="pmc">PMC4681411</ArticleId>
            <ArticleId IdType="pubmed">26163333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weis WI, Taylor ME, Drickamer K. The C‐type lectin superfamily in the immune system. Immunol Rev. 1998;163:19‐34. doi:10.1111/j.1600-065x.1998.tb01185.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065x.1998.tb01185.x</ArticleId>
            <ArticleId IdType="pubmed">9700499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chaipan C, Soilleux EJ, Simpson P, et al. DC‐SIGN and CLEC‐2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol. 2006;80:8951‐8960. doi:10.1128/JVI.00136-06
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.00136-06</ArticleId>
            <ArticleId IdType="pmc">PMC1563896</ArticleId>
            <ArticleId IdType="pubmed">16940507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suzuki‐Inoue K, Fuller GL, Garcia A, et al. A novel Syk‐dependent mechanism of platelet activation by the C‐type lectin receptor CLEC‐2. Blood. 2006;107:542‐549. doi:10.1182/blood-2005-05-1994
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2005-05-1994</ArticleId>
            <ArticleId IdType="pubmed">16174766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suzuki‐Inoue K, Inoue O, Ding G, et al. Essential in vivo roles of the C‐type lectin receptor CLEC‐2: embryonic/neonatal lethality of CLEC‐2–deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC‐2‐deficient platelets. J Biol Chem. 2010;285:24494‐24507. doi:10.1074/jbc.M110.130575
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.130575</ArticleId>
            <ArticleId IdType="pmc">PMC2915686</ArticleId>
            <ArticleId IdType="pubmed">20525685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Osada M, Inoue O, Ding G, et al. Platelet activation receptor CLEC‐2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. J Biol Chem. 2012;287:22241‐22252. doi:10.1074/jbc.M111.329987
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.329987</ArticleId>
            <ArticleId IdType="pmc">PMC3381185</ArticleId>
            <ArticleId IdType="pubmed">22556408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chacko GW, Duchemin AM, Coggeshall KM, Osborne JM, Brandt JT, Anderson CL. Clustering of the platelet Fc gamma receptor induces noncovalent association with the tyrosine kinase p72syk. J Biol Chem. 1994;269:32435‐32440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7798242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hughes CE, Pollitt AY, Mori J, et al. CLEC‐2 activates Syk through dimerization. Blood. 2010;115:2947‐2955. doi:10.1182/blood-2009-08-237834
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-08-237834</ArticleId>
            <ArticleId IdType="pmc">PMC4361903</ArticleId>
            <ArticleId IdType="pubmed">20154219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watson AA, Christou CM, James JR, et al. The platelet receptor CLEC‐2 is active as a dimer. Biochemistry. 2009;48:10988‐10996. doi:10.1021/bi901427d
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi901427d</ArticleId>
            <ArticleId IdType="pubmed">19824697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watson SP, Asazuma N, Atkinson B, et al. The role of ITAM‐ and ITIM‐coupled receptors in platelet activation by collagen. Thromb Haemost. 2001;86:276‐288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11487016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Manne BK, Badolia R, Dangelmaier C, et al. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets. J Biol Chem. 2015;290:11557‐11568. doi:10.1074/jbc.M114.629527
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.629527</ArticleId>
            <ArticleId IdType="pmc">PMC4416859</ArticleId>
            <ArticleId IdType="pubmed">25767114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nicolson PLR, Nock SH, Hinds J, et al. Low dose Btk inhibitors selectively block platelet activation by CLEC‐2. Haematologica. 2020;106(1):208‐219. doi:10.3324/haematol.2019.218545
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2019.218545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chari R, Kim S, Murugappan S, Sanjay A, Daniel JL, Kunapuli SP. Lyn, PKC‐delta, SHIP‐1 interactions regulate GPVI‐mediated platelet‐dense granule secretion. Blood. 2009;114:3056‐3063. doi:10.1182/blood-2008-11-188516
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2008-11-188516</ArticleId>
            <ArticleId IdType="pmc">PMC2756209</ArticleId>
            <ArticleId IdType="pubmed">19587372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kostyak JC, Mauri BR, Dangelmaier C, et al. TULA‐2 deficiency enhances platelet functional responses to CLEC‐2 agonists. TH Open. 2018;2:e411‐e419. doi:10.1055/s-0038-1676358
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0038-1676358</ArticleId>
            <ArticleId IdType="pmc">PMC6524918</ArticleId>
            <ArticleId IdType="pubmed">31249969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
May F, Hagedorn I, Pleines I, et al. CLEC‐2 is an essential platelet‐activating receptor in hemostasis and thrombosis. Blood. 2009;114:3464‐3472. doi:10.1182/blood-2009-05-222273
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-05-222273</ArticleId>
            <ArticleId IdType="pubmed">19641185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Christou CM, Pearce AC, Watson AA, et al. Renal cells activate the platelet receptor CLEC‐2 through podoplanin. Biochem J. 2008;411:133‐140. doi:10.1042/BJ20071216
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20071216</ArticleId>
            <ArticleId IdType="pmc">PMC2749330</ArticleId>
            <ArticleId IdType="pubmed">18215137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suzuki‐Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC‐2, in podoplanin‐mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993‐26001. doi:10.1074/jbc.M702327200
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M702327200</ArticleId>
            <ArticleId IdType="pubmed">17616532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gitz E, Pollitt AY, Gitz‐Francois JJ, et al. CLEC‐2 expression is maintained on activated platelets and on platelet microparticles. Blood. 2014;124:2262‐2270. doi:10.1182/blood-2014-05-572818
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-05-572818</ArticleId>
            <ArticleId IdType="pmc">PMC4183985</ArticleId>
            <ArticleId IdType="pubmed">25150298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zeiler M, Moser M, Mann M. Copy number analysis of the murine platelet proteome spanning the complete abundance range. Mol Cell Proteomics. 2014;13:3435‐3445. doi:10.1074/mcp.M114.038513
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M114.038513</ArticleId>
            <ArticleId IdType="pmc">PMC4256495</ArticleId>
            <ArticleId IdType="pubmed">25205226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost. 2005;3:1752‐1762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16102042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood. 2003;102:3592‐3599. doi:10.1182/blood-2003-04-1142
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2003-04-1142</ArticleId>
            <ArticleId IdType="pubmed">12842985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Severin S, Pollitt AY, Navarro‐Nunez L, et al. Syk‐dependent phosphorylation of CLEC‐2: a novel mechanism of hem‐immunoreceptor tyrosine‐based activation motif signaling. J Biol Chem. 2011;286:4107‐4116. doi:10.1074/jbc.M110.167502
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.167502</ArticleId>
            <ArticleId IdType="pmc">PMC3039337</ArticleId>
            <ArticleId IdType="pubmed">21098033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watson AA, O'Callaghan CA. Molecular analysis of the interaction of the snake venom rhodocytin with the platelet receptor CLEC‐2. Toxins. 2011;3:991‐1003. doi:10.3390/toxins3080991
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins3080991</ArticleId>
            <ArticleId IdType="pmc">PMC3202865</ArticleId>
            <ArticleId IdType="pubmed">22069753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suzuki‐Inoue K, Ozaki Y, Kainoh M, et al. Rhodocytin induces platelet aggregation by interacting with glycoprotein Ia/IIa (GPIa/IIa, Integrin alpha 2beta 1). Involvement of GPIa/IIa‐associated Src and protein tyrosine phosphorylation. J Biol Chem. 2001;276:1643‐1652. doi:10.1074/jbc.M006191200
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M006191200</ArticleId>
            <ArticleId IdType="pubmed">11038351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Martin EM, Zuidscherwoude M, Moran LA, Di Y, Garcia A, Watson SP. The structure of CLEC‐2: mechanisms of dimerization and higher‐order clustering. Platelets. 2021;32:733‐743. doi:10.1080/09537104.2021.1906407
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09537104.2021.1906407</ArticleId>
            <ArticleId IdType="pubmed">33819136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wahl MI, Fluckiger AC, Kato RM, Park H, Witte ON, Rawlings DJ. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton’s tyrosine kinase via alternative receptors. Proc Natl Acad Sci U S A. 1997;94:11526‐11533. doi:10.1073/pnas.94.21.11526
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.94.21.11526</ArticleId>
            <ArticleId IdType="pmc">PMC23526</ArticleId>
            <ArticleId IdType="pubmed">9326643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Urzainqui A, Serrador JM, Viedma F, et al. ITAM‐based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL‐1. Immunity. 2002;17:401‐412. doi:10.1016/s1074-7613(02)00420-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1074-7613(02)00420-x</ArticleId>
            <ArticleId IdType="pubmed">12387735</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
